A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours

BACKGROUND: Veliparib is a potent poly(ADP-ribose) polymerase inhibitor. This phase 1 study aimed to establish the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of veliparib combined with various FOLFIRI regimens in patients with solid tumours. METHODS: Patients received veliparib...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Br J Cancer
Main Authors: Berlin, Jordan, Ramanathan, Ramesh K., Strickler, John H., Subramaniam, Deepa S., Marshall, John, Kang, Yoon-Koo, Hetman, Robert, Dudley, Matthew W., Zeng, Jiewei, Nickner, Caroline, Xiong, Hao, Komarnitsky, Philip, Shepherd, Stacie Peacock, Hurwitz, Herbert, Lenz, Heinz-Josef
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2018
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5933261/
https://ncbi.nlm.nih.gov/pubmed/29527010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0003-3
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki